
The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonwealth University discussed new data supporting the potential of GLP-1 RAs as a non-surgical option for idiopathic intracranial hypertension. [WATCH TIME: 3 minutes]
The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonwealth University discussed new data supporting the potential of GLP-1 RAs as a non-surgical option for idiopathic intracranial hypertension. [WATCH TIME: 3 minutes]
The advisory board member of the Parkinson's Foundation shared personal insights on how love, present-moment awareness, and hope shaped her approach to living with the Parkinson disease. [WATCH TIME: 6 minutes]
The professor of molecular neurology at the University of Cambridge highlighted recent research on tau protein aggregation in Alzheimer disease and other related tauopathies. [WATCH TIME: 6 minutes]
Panelists discuss how treatment decisions for complex cases like the 66-year-old man with severe dyskinesia and 4 hours of daily “off” time require individualized approaches based on patient tolerance, with options including delayed-release/extended-release amantadine (starting at lower doses in older patients due to hallucination risk), extended-release carbidopa-levodopa formulations, infusion pumps for potential deep priming effects, or deep brain stimulation for patients seeking rapid improvement, emphasizing the importance of engaging patients in discussions about their patience for dose adjustments, risk tolerance for adverse effects, and desired timeline for symptom control to guide optimal treatment selection.
Panelists discuss how excessive daytime sleepiness significantly impacts patients' work productivity and quality of life, yet many patients rationalize their symptoms as normal or fail to recognize the severity of their condition, making thorough clinical questioning essential.
Panelists discuss how to differentiate true excessive daytime sleepiness from general fatigue or tiredness, emphasizing the importance of collaborative care with other specialists to address underlying mood disorders and comorbid conditions that may complicate diagnosis.
The director of neurosurgical pain division at Allegheny General Hospital highlighted the push to intervene earlier with neurosurgical treatments for chronic pain, including diabetic neuropathy. [WATCH TIME: 4 minutes]
Panelists discuss how a 66-year-old man with 8 years of Parkinson disease presenting with severe peak-dose dyskinesia affecting basic functions like eating and speaking, plus 4 hours of daily “off” time despite frequent dosing, represents a patient who should not have been allowed to progress to such advanced motor complications, emphasizing that the preferred approach is early intervention to treat motor fluctuations and dyskinesia as they develop rather than waiting until patients reach this severely impaired state with complex symptoms requiring more intensive management strategies.
The Emeritus Professor of Cognitive Neurology at VU University Medical Center talked about findings presented at AAIC 2025 from the phase 3 BROADWAY trial of obicetrapib in Alzheimer disease. [WATCH TIME: 3 minutes]
Neurology News Network. for the week ending August 2, 2025. [WATCH TIME: 4 minutes]
The chief development officer at Spinogenix shared initial results from the first cohort of the company’s phase 2 trial assessing SPG302 in Alzheimer disease presented at AAIC 2025. [WATCH TIME: 6 minutes]
The senior data scientist at Linus Health discussed how acoustic and speech-based metrics can be used to capture subtle cognitive signals during neuropsychological assessments. [WATCH TIME: 6 minutes]
The chief scientific officer at Neurogen Biomarking outlined a novel home-based diagnostic model that can accelerate detection of early AD through biomarker profiling. [WATCH TIME: 5 minutes]
In this final episode, the sleep experts analyze real-world prescribing data to understand how low-sodium oxybate impacts the use of traditional alerting agents in narcolepsy. [WATCH TIME: 4 minutes]
The associate professor of neurology at Icahn School of Medicine at Mount Sinai discussed the clinical and scientific advantages of blood-based biomarkers over imaging for Alzheimer disease. [WATCH TIME: 5 minutes]
At AAIC 2025, the chief medical officer at CND Life Sciences discussed recent progress in detecting neurodegenerative diseases earlier using tools like the Syn-One Test. [WATCH TIME: 3 minutes]
In episode 5, the sleep specialists examine actigraphy data from a study of TAK-861 in narcolepsy type 1 and discuss the promise of home-based sleep tracking in clinical care. [WATCH TIME: 3 minutes]
Panelists discuss how the traditional profile of older, overweight men with thick necks remains valid for OSA risk, but clinicians must also recognize that less obvious cases in younger, smaller individuals can be easily missed and require more sensitive screening approaches.
Panelists discuss how treatment options for advanced Parkinson disease patients like the 54-year-old woman include deep brain stimulation (DBS) as an excellent choice given her young age and cognitive status, with amantadine delayed-release/extended-release showing robust effects comparable to DBS (about 3 hours of increased good “on” time) in patients meeting DBS criteria, while newer infusion therapies may offer potential benefits through both pharmacokinetic effects from reducing peak-trough levels and a theoretical "deep priming" process that could reset hypersensitive dopamine receptors by providing continuous stimulation, though more research data is needed to confirm these hypothetical benefits.
Panelists discuss how delayed-release/extended-release amantadine represents a unique treatment option for patients like the 54-year-old woman with both dyskinesia and “off” time, as it is the only FDA-approved medication that addresses both conditions simultaneously, with its bedtime dosing and pharmacokinetic profile providing overnight absorption and sustained daytime levels that resulted in phase 3 trials showing a 40% reduction in dyskinesia and 2.4 hours of increased good “on” time, making it an ideal first-line treatment for patients who have both troublesome dyskinesia and motor fluctuations rather than simply reducing dopaminergic medications which would worsen motor symptoms.
Panelists discuss how obstructive sleep apnea affects potentially up to 1 billion people globally, with excessive daytime sleepiness being a common but often underreported presenting complaint that patients may not recognize or admit to experiencing.
In this segment, Eric Olson, MD, and Anita Shelgikar, MD, discuss the design of the Vibrance-3 trial, a phase 2 study of the orexin-2 receptor agonist ALKS 2680 in patients with idiopathic hypersomnia. [WATCH TIME: 4 minutes]
In episode 3, Drs. Olson and Shelgikar break down a retrospective study exploring how social determinants of health impact the clinical experience of patients with narcolepsy. [WATCH TIME: 6 minutes]
Neurology News Network. for the week ending July 26, 2025. [WATCH TIME: 4 minutes]
Panelists Eric Olson, MD, and Anita Shelgikar, MD, examine interim data on high-dose low-sodium oxybate in patients with narcolepsy, discussing safety signals, efficacy trends, and clinical considerations. [WATCH TIME: 4 minutes]
A panelist discusses the importance of obtaining a comprehensive sleep history before prescribing medication for chronic insomnia and highlights the growing role of dual orexin receptor antagonists (DORAs) as a safer, first-line treatment option with fewer adverse effects compared to older sleep medications like benzodiazepines.
The postdoctoral neuropsychology fellow at North Shore University Hospital talked about recognizing and aligning subjective cognitive complaints with objective assessments in patients with migraine during the interictal period. [WATCH TIME: 6 minutes]
In this episode, Eric Olson, MD, and Anita Shelgikar, MD, review the XYLO study’s findings on the impact of switching from high- to low-sodium oxybate on blood pressure in patients with narcolepsy.
The chief program officer at PMD Alliance described an interactive program designed to help health care providers better understand the lived experience of patients with Parkinson disease and related movement disorders. [WATCH TIME: 6 minutes]
The head of medical development for donanemab at Eli Lilly and Company explained how donanemab’s modified titration dosing regimen could reduce ARIA risk and improve clinical decision-making following the drug’s FDA label update. [WATCH TIME: 3 minutes]